ADR120S, Inc. (TYO:3750)
Japan · Delayed Price · Currency is JPY 791.00
-2.00 (-0.25%)
Jun 3, 2026, 3:30 PM JST
ADR120S Revenue
In the fiscal year ending March 31, 2026, ADR120S had annual revenue of 50.00M JPY, down -59.02%. ADR120S had revenue of 17.00M in the quarter ending March 31, 2026, with 142.86% growth.
Revenue
50.00M
Revenue Growth
-59.02%
P/S Ratio
141.60
Revenue / Employee
5.00M
Employees
10
Market Cap
7.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 50.00M | -72.00M | -59.02% |
| Mar 31, 2025 | 122.00M | -1.44B | -92.18% |
| Mar 31, 2024 | 1.56B | -584.00M | -27.24% |
| Mar 31, 2023 | 2.14B | 809.00M | 60.60% |
| Mar 31, 2022 | 1.34B | -53.00M | -3.82% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.59B |
| Soiken Holdings | 4.40B |
| CellSource | 3.72B |
| StemCell Institute | 2.81B |
| MEDINET | 998.00M |
| OncoTherapy Science | 808.00M |
| Carna Biosciences | 618.65M |
| Chiome Bioscience | 593.29M |